Form 4: Moderna Director Sandra Horning Receives Equity Grant

Moderna Director Sandra Horning was granted stock options and restricted stock units as part of annual compensation.

Summary

• Director Sandra Horning received a grant of 9,681 stock options with an exercise price of $48.79.
• Director Sandra Horning received a grant of 2,092 restricted stock units (RSUs).
• Both the stock options and RSUs are scheduled to vest on the earlier of May 6, 2027, or the next Annual Meeting of Shareholders.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral, routine administrative filing regarding director compensation that does not signal a change in company strategy or financial health.

Positives

• Equity-based compensation aligns the interests of the director with those of long-term shareholders.

Negatives

• The issuance of new equity awards results in minor dilution to existing shareholders.

Risks

• Vesting is subject to the recipient's continued service to the company.

Future Outlook

The equity grants are subject to standard vesting conditions based on continued service through May 2027 or the next annual meeting.

Industry Context

StockSavvy.ai notes that this is a routine disclosure of director compensation, which is standard practice for publicly traded biotechnology companies to incentivize board members.

Comparison to Industry Standards

• The grant of equity to non-employee directors is consistent with standard corporate governance practices in the pharmaceutical and biotech sectors.
• Vesting periods of one year for director equity are common among large-cap biotech firms like Pfizer, Amgen, and Gilead.

Stakeholder Impact

• Minor dilution for existing shareholders due to the issuance of new equity awards.

Next Steps

• Vesting of equity awards on May 6, 2027, or the next Annual Meeting of Shareholders.

Key Dates

Keywords

Moderna, MRNA, Form 4, Insider Trading, Equity Compensation, Director Compensation